Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
9.14
-0.17 (-1.83%)
Jun 27, 2025, 4:00 PM - Market closed
Evolus Employees
Evolus had 332 employees as of December 31, 2024. The number of employees increased by 59 or 21.61% compared to the previous year.
Employees
332
Change (1Y)
59
Growth (1Y)
21.61%
Revenue / Employee
$829,708
Profits / Employee
-$169,286
Market Cap
589.31M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EOLS News
- 14 days ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 17 days ago - Evolysse™ Recognized in 2025 Shape Skin Awards - Business Wire
- 4 weeks ago - Evolus Announces Departure of its Chief Financial Officer - Business Wire
- 5 weeks ago - Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - Business Wire
- 7 weeks ago - Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Evolus Reports First Quarter 2025 Results - Business Wire
- 7 weeks ago - Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility - Business Wire
- 2 months ago - Evolus to Report First Quarter Financial Results on May 7, 2025 - Business Wire